Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications

Hammad Tashkandi, Xiaohui Zhang, Rami S. Komrokji, Najla H. Al Ali, Zhuoer Xie, Alison R. Walker, Eric Padron, Jeffrey E Lancet, David Sallman, Ling Zhang

Blood (2024) 144 (Supplement 1): 3227.

https://doi.org/10.1182/blood-2024-211460

Published: 2024

Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman

Blood (2022) 140 (Supplement 1): 3435–3437.

https://doi.org/10.1182/blood-2022-171197

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T. Kuykendall, Eric Padron, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Jeffrey E. Lancet

Blood (2021) 138 (Supplement 1): 686.

https://doi.org/10.1182/blood-2021-150759

Published: 2021